View Item 

Show simple item record

Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis
dc.contributor.authorStifano, Giuseppina
dc.contributor.authorSornasse, Thierry
dc.contributor.authorRice, Lisa M.
dc.contributor.authorNa, Leo
dc.contributor.authorChen‐harris, Haiyin
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorJahreis, Angelika
dc.contributor.authorZhang, Yuqing
dc.contributor.authorSiegel, Jeff
dc.contributor.authorLafyatis, Robert
dc.date.accessioned2018-06-11T17:59:56Z
dc.date.available2019-08-01T19:53:23Zen
dc.date.issued2018-06
dc.identifier.citationStifano, Giuseppina; Sornasse, Thierry; Rice, Lisa M.; Na, Leo; Chen‐harris, Haiyin ; Khanna, Dinesh; Jahreis, Angelika; Zhang, Yuqing; Siegel, Jeff; Lafyatis, Robert (2018). "Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis." Arthritis & Rheumatology 70(6): 912-919.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/144268
dc.publisherJohn Wiley & Sons
dc.titleSkin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144268/1/art40455.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144268/2/art40455_am.pdf
dc.identifier.doi10.1002/art.40455
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferencePendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PloS One 2010; 5: e12106.
dc.identifier.citedreferenceOkano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993; 119: 1005 â 13.
dc.identifier.citedreferenceStifano G, Affandi AJ, Mathes AL, Rice LM, Nakerakanti S, Nazari B, et al. Chronic Tollâ like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor β signature gene expression, and fibrosis. Arthritis Res Ther 2014; 16: R136.
dc.identifier.citedreferenceKhanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387: 2630 â 40.
dc.identifier.citedreferenceHoffmannâ La Roche, sponsor. A phase II/III multicenter, randomized, doubleâ blind, placeboâ controlled study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis. ClinicalTrials.gov identifier: NCT01532869; 2012.
dc.identifier.citedreferenceNagin DS, Odgers CL. Groupâ based trajectory modeling in clinical research. Annu Rev Clin Psychol 2010; 6: 109 â 38.
dc.identifier.citedreferenceJones B, Nagin D, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Soc Meth Res 2001; 29: 374 â 93.
dc.identifier.citedreferenceDavid W, Hosmer J, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. New York: John Wiley & Sons; 2013. p. 528.
dc.identifier.citedreferenceSubcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 â 90.
dc.identifier.citedreferenceRice LM, Ziemek J, Stratton EA, McLaughlin SR, Padilla CM, Mathes AL, et al. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2015; 67: 3004 â 15.
dc.identifier.citedreferenceMerkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient metaâ analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2012; 64: 3420 â 9.
dc.identifier.citedreferenceMaurer B, Graf N, Michel BA, Müllerâ Ladner U, Czirják L, Denton CP, et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2015; 74: 1124 â 31.
dc.identifier.citedreferenceYork MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A macrophage marker, Siglecâ 1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Tollâ like receptor agonists. Arthritis Rheum 2007; 56: 1010 â 20.
dc.identifier.citedreferenceChristmann RB, Hayes E, Pendergrass S, Padilla C, Farina G, Affandi AJ, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosisâ associated pulmonary arterial hypertension. Arthritis Rheum 2011; 63: 1718 â 28.
dc.identifier.citedreferenceRice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015; 125: 2795 â 807.
dc.identifier.citedreferenceWahl SM, Hunt DA, Wakefield LM, McCartneyâ Francis N, Wahl LM, Roberts AB, et al. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A 1987; 84: 5788 â 92.
dc.identifier.citedreferenceLund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, et al. Transforming growth factorâ β is a strong and fast acting positive regulator of the level of typeâ 1 plasminogen activator inhibitor mRNA in WIâ 38 human lung fibroblasts. EMBO J 1987; 6: 1281 â 6.
dc.identifier.citedreferenceGewin L, Zent R. How does TGFâ β mediate tubulointerstitial fibrosis? Semin Nephrol 2012; 32: 228 â 35.
dc.identifier.citedreferenceInagaki Y, Higashiyama R, Higashi K. Novel antiâ fibrotic modalities for liver fibrosis: molecular targeting and regenerative medicine in fibrosis therapy. J Gastroenterol Hepatol 2012; 27 Suppl 2: 85 â 8.
dc.identifier.citedreferenceMaher TM. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012; 33: 69 â 83.
dc.identifier.citedreferenceMozaffarian A, Brewer AW, Trueblood ES, Luzina IG, Todd NW, Atamas SP, et al. Mechanisms of oncostatin Mâ induced pulmonary inflammation and fibrosis. J Immunol 2008; 181: 7243 â 53.
dc.identifier.citedreferenceFeeney M, Syed F, Khan K, Shiwen X, Sully K, Trinder S, et al. Oncostatin M as a potential molecular target in systemic sclerosis [abstract]. Arthritis Rheumatol 2015; 67 Suppl 10. URL: http://acrabstracts.org/abstract/oncostatin-m-as-a-potential-molecular-target-in-systemic-sclerosis/.
dc.identifier.citedreferenceHoffmanâ La Roche, sponsor. A phase III, multicenter, randomized, doubleâ blind, placeboâ controlled, parallelâ group study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis. ClinicalTrials.gov identifier: NCT02453256; 2015.
dc.identifier.citedreferenceClements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892 â 6.
dc.identifier.citedreferenceDeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al. Predictors and outcomes of scleroderma renal crisis: the highâ dose versus lowâ dose Dâ penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983 â 9.
dc.identifier.citedreferenceSteen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437 â 44.
dc.identifier.citedreferenceShand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56: 2422 â 31.
dc.identifier.citedreferenceDomsic RT. Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol 2014; 26: 646 â 52.
dc.identifier.citedreferenceMaurer B, Graf N, Michel BA, Müllerâ Ladner U, Czirják L, Denton CP, et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2015; 74: 1124 â 31.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art40455.pdf
Size:
404.9KB
Format:
PDF
View/Open
Name:
art40455_am.pdf
Size:
436.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.